Table 2.

Therapeutic antibodies undergoing phase 3 clinical trials for Tau-associated neurodegenerative conditions (December 2022; ClinicalTrials.gov)

Name	Role	Clinical trial registration
Donanemab	Aβ Monoclonal Antibody	Phase 3, recruiting (NCT05508789)
E2814 vs. Lecanemab	Anti-microtubule-binding region (MTBR) tau antibody vs. Aβ Monoclonal Antibody	Phase 3, recruiting (NCT05269394)
Remternetug	Aβ Monoclonal Antibody	Phase 3, recruiting (NCT05463731)
Aducanumab	Aβ Monoclonal Antibody	Phase 3, recruiting (NCT05310071)
Gantenerumab	Aβ fibril Monoclonal Antibody	Phase 3, active (NCT05256134)

Following the apparent success of Lecanemab (van Dyck et al., 2022), many of these antibodies target the Aβ cascade, however, E2814, an antibody against the microtubule-binding region of Tau, is also being compared to lecanemab in a clinical trial (NCT05269394).